SK Bioscience signs 23.9 billion KRW contract with Korea's Public Procurement Service for 2026-2027 flu vaccine supply, reinforcing recurring revenue
SK Bioscience has signed a supply contract with the Public Procurement Service of Korea for the 2026-2027 season influenza vaccine, valued at 23.9 billion KRW including VAT.
The contract accounts for approximately 3.67% of the company's 2025 consolidated revenue of 651.4 billion KRW, ensuring stable revenue generation from routine government procurement.
The counterparty is a government agency with extremely low credit risk. Quantity may be adjusted within 10% by the demand agency, the Korea Disease Control and Prevention Agency, and further by mutual agreement.
[AI Summary]This routine supply contract has limited direct impact on the stock price but reinforces revenue stability in the vaccine business. There is no capital dilution or governance risk, and the government counterparty provides high credit quality, a positive factor for conservative investors.